AMIR, SRY AGSHARY (2013) EVALUASI PENERAPAN SISTEM BIAYA BERBAGI KEMOTERAPI PASIEN KANKER SERVIKS DI RSUD Dr. MOEWARDI SURAKARTA PERIODE 2012. Tesis thesis, Universitas setia budi.
![[img]](http://repo.setiabudi.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (89kB) |
|
Text
BAB I.pdf Download (372kB) |
|
Text
BAB II.pdf Restricted to Repository staff only Download (248kB) | Request a copy |
|
Text
BAB III.pdf Download (98kB) |
|
Text
BAB IV.pdf Restricted to Repository staff only Download (133kB) | Request a copy |
|
Text
BAB V.pdf Restricted to Repository staff only Download (83kB) | Request a copy |
|
Text
BAB VI.pdf Download (777kB) |
Abstract
One of the diseases that require special attention in terms of finance, is cervical cancer. The cost of chemotherapy is expensive so attemps to do in terms of financing hospital chemotherapy for cervical cancer patients is of cost sharing among cervical cancer patients . The purpose of this study was determine how the patterns of chemotherapy of cervical cancer and the difference in cost to the system without the application of cost sharing (Cost Sharing) and find out the amount of savings. The methods of study is a retrospective study use data on 350 cervical cancer patients hwo use medication during the period 2012 in Hospital Dr. Moewardi Hospital Surakarta. Data be taken from protocol every patient in the pharmacies UDSS. Data use includes the cost of chemotherapy drugs, solvents and equipment used at the time of reconstitution. The calculated cost of drug, solvent devices in the reconstitution. Data analysis was performed to obtain any or no differences in system implementation and if not implementation cost-sharing system and the amount of savings made by the patient. The results showed that the patterns of chemotherapy of cervical cancer patients in hospitals Dr. Moewardi Surakarta includes fluracedyl, cisplatin, paclitaxel, carboplatin, bleomycin, vincristin dan gemzar. The results of this study also showed there were the differences in the cost no implementation cost-sharing system and the implementation of cost-sharing system. In the cost analysis in mind the cost of the application of cost sharing amounted Rp 757.281.642,00. The savings on the application cost sharing system is 89.144.945. So that it can be concluded that the application of cost-sharing is more efficient than not applicatin of cost-sharing system. Key words: cervical cancer, cost sharing, chemotherapy.
| Item Type: | Thesis (Tesis) |
|---|---|
| Additional Information: | Prof. Dr. Achmad Fudholi, DEA,. Apt ; Dr. Gunawan Pamudji Widodo, M.Si., Apt |
| Uncontrolled Keywords: | Key words: cervical cancer, cost sharing, chemotherapy. |
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Divisions: | Fakultas Farmasi > Prodi S2 Farmasi |
| Depositing User: | Mrs NOVI HANDAYANI |
| Date Deposited: | 01 Nov 2019 07:45 |
| Last Modified: | 01 Nov 2019 07:45 |
| URI: | http://repo.setiabudi.ac.id/id/eprint/3215 |
Actions (login required)
 |
View Item |
